Ideaya Biosciences (IDYA) on Sunday said it selected IDE101 as a drug candidate for further development to treat cancers lacking CDKN2A, a gene that normally helps prevent uncontrolled cell growth. The company aims to seek U.S. regulatory permission to begin human testing
Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stocks, cryptocurrency, real estate, finance, and much more.